🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Börje S. Andersson

The University of Texas MD Anderson Cancer Center

ORCID: 0000-0003-4761-0220

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation”.

Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation

Journal of Clinical Oncology(2021)10.1200/jco.20.02608

N/A

2.1DataRank · unranked

66 citations

Ruitao Lin, David Marín, Hind Rafei, Mustafa Bdiwi, Peter F. Thall +38 more

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008668

N/A

0.742DataRank · unranked

29 citations

Tobias A.W. Holderried, Jason J. Luke, Van K. Morris, Winfried Alsdorf, Katrin Wetzko +27 more

Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy

Journal of Hematology & Oncology(2023)10.1186/s13045-023-01504-7

N/A

0.663DataRank · unranked

82 citations

Börje S. Andersson, Mehmet A. Baysal, Jason S. Damiano, Apostolia M. Tsimberidou, Yannick Bulliard

Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Cancer Immunology Research(2023)10.1158/2326-6066.cir-22-0444

N/A

0.656DataRank · unranked

14 citations

Kerstin Guenther, Börje S. Andersson, Regina Mendrzyk, Amir Alpert, Claudia Wagner +36 more

Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities

Blood Advances(2023)10.1182/bloodadvances.2023010850

N/A

0.462DataRank · unranked

12 citations

Oren Pasvolsky, Roland L. Bassett, Rohtesh S. Mehta, Amanda Olson, Julianne Chen +21 more

HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: Implications for their use in combination with PARP inhibitors and chemotherapeutic drugs

Oncotarget(2022)10.18632/oncotarget.28278

N/A

0.457DataRank · unranked

20 citations

Yago Nieto, Bin Yuan, David Murray, Börje S. Andersson, Benigno C. Valdez

Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells

Experimental Hematology(2020)10.1016/j.exphem.2020.01.003

N/A

0.406DataRank · unranked

14 citations

Yang Li, David Murray, Yan Liu, Yago Nieto, Qaiser Bashir +3 more

A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation

Bone Marrow Transplantation(2022)10.1038/s41409-022-01705-7

N/A

0.360DataRank · unranked

10 citations

Peter F. Thall, Junsheng Ma, Benigno C. Valdez, Roland L. Bassett, Julianne Chen +20 more

Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations

International Journal of Molecular Sciences(2024)10.3390/ijms25179241

N/A

0.330DataRank · unranked

8 citations

Apostolia M. Tsimberidou, Bin Yuan, Mehmet A. Baysal, Abhijit Chakraborty, Clark R. Andersen +2 more

Synergistic cytotoxicity of fludarabine, clofarabine, busulfan, vorinostat and olaparib in AML cells

Frontiers in Oncology(2023)10.3389/fonc.2023.1287444

N/A

0.330DataRank · unranked

8 citations

Bin Yuan, David Murray, Jeremy Ramdial, Yago Nieto, Uday Popat +3 more

ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells

Oncotarget(2024)10.18632/oncotarget.28563

N/A

0DataRank · unranked

6 citations

Bin Yuan, David Murray, Jeremy Ramdial, Uday Popat, Yago Nieto +2 more

Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells

Leukemia & lymphoma/Leukemia and lymphoma(2022)10.1080/10428194.2022.2042689

N/A

0DataRank · unranked

8 citations

Bin Yuan, David Murray, Yago Nieto, Uday Popat, Börje S. Andersson +1 more

High-Dose Chemotherapy for Multiply or Poor-Risk Relapsed Germ Cell Tumors

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1917

N/A

0DataRank · unranked

2 citations

John F. Ward, Wayne L. Hofstetter, David C. Rice, José A. Karam, Louis L. Pisters +24 more

Autologous engineered T cell receptor therapy in advanced cancer

Human Vaccines & Immunotherapeutics(2023)10.1080/21645515.2023.2290356

N/A

0DataRank · unranked

5 citations

Mehmet A. Baysal, Abhijit Chakraborty, Börje S. Andersson, Apostolia M. Tsimberidou

ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells

Oncotarget(2022)10.18632/oncotarget.28193

N/A

0DataRank · unranked

15 citations

David Murray, Bin Yuan, Yago Nieto, Uday Popat, Börje S. Andersson +1 more